BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...started clinical testing of its first allogeneic CAR T cell therapy UCART19 in 2016 and UCART123...
...resume, and efficacy data is just starting to emerge. Cellectis will present preclinical data on UCART123...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

...allogeneic CAR Ts in oncology are UCART19 from Allogene and Servier, ALLO-501 from Allogene, and UCART123...
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...now being developed by Allogene in the U.S. and Servier outside the U.S. Cellectis has UCART123...
...plus anti-CD52 antibody therapy; insertion of CD19-targeting CAR TALEN Phase I Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) UCART123...
BioCentury | Apr 13, 2018
Financial News

Cellectis plans to use funds for UCART development and commercialization

...accompanied its $175 million follow-on from earlier this month (see BioCentury, April 6) . Cellectis' UCART123...
BioCentury | Apr 6, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

...and a Phase I trial for its wholly-owned UCART123. FDA placed a clinical hold on UCART123...
...in the toxicity profile between allo[geneic] and auto[logus]" (see BioCentury Innovations, Feb. 4, 2016 ). UCART123...
BioCentury | Apr 3, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

...and a Phase I trial for its wholly-owned UCART123. FDA placed a clinical hold on UCART123...
...in the toxicity profile between allo[geneic] and auto[logus]" (see BioCentury Innovations, Feb. 4, 2016) . UCART123...
...Tuesday, Celyad slipped €1.46 to €26.80 in Brussels and fell $1.46 to $32.54 on NASDAQ. Jennie Walters UCART123 UCART19 Cellectis...
BioCentury | Feb 23, 2018
Company News

Cellectis granted U.S. patents for CRISPR T cell therapies

...out the use of CRISPR for drug development in the future. Cellectis’ TALEN-based UCART19 and UCART123...
...BioCentury Innovations, Nov. 10, 2016 ). Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), Paris, France Business: Gene/Cell therapy Mary Romeo UCART123 UCART19 Cellectis...
BioCentury | Nov 17, 2017
Clinical News

FDA lifts clinical hold on Cellectis' CAR T candidate

...clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123...
...to 6.25x10 4 cells/kg. A 78-year-old male patient in the Phase I ABC study of UCART123...
...two patients across the two studies. The Phase I AML123 and ABC trials are evaluating UCART123...
BioCentury | Nov 7, 2017
Clinical News

FDA lifts clinical hold on Cellectis' CAR T candidate

...clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123...
...studies to 6.25x10^4 cells/kg. A 78-year-old male patient in the Phase I ABC study of UCART123...
...ABC trials are evaluating UCART123 in patients with relapsed or refractory AML or BPDCN, respectively. UCART123...
BioCentury | Sep 8, 2017
Clinical News

FDA places hold on Phase I testing of Cellectis' CAR T UCART123

...clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123...
...FDA, which would include lowered dosing. The Phase I ABC and AML123 trials were evaluating UCART123...
...capillary leak syndrome ( CLS ) after receiving a single IV infusion of 6.25x10 5 UCART123...
Items per page:
1 - 10 of 23